Industries
Clinical Research
Sponsors, sites and research organizations are evaluated on whether the data submitted can be reconstructed and trusted. We help clinical organizations build the quality practices that make that possible.
xFDA supports sponsors, CROs and investigator sites with GCP compliance, clinical quality management systems, site and vendor audits, data integrity, protocol deviation and clinical CAPA programs, and BIMO-focused technical readiness.
How we support this sector
Where engagements typically focus
- Clinical quality management systems and SOP frameworks
- Sponsor oversight of CROs, laboratories and vendors
- Investigator site audits and corrective action support
- Trial master file review and inspection readiness
- Protocol deviation management and clinical CAPA
- BIMO preparation for sponsors, monitors and sites
Our founder conducted GCP inspections while at FDA, which informs how we assess clinical quality systems.
When companies call us
Situations we are asked into
- A pivotal study is approaching database lock and sponsor oversight documentation is thin.
- Protocol deviations are logged but never analyzed for systemic cause.
- A CRO is performing monitoring the sponsor cannot evidence it reviewed.
- Source data at a site cannot reconstruct what was reported in the eCRF.
- A trial master file has gaps that would be visible in any inspection.
Clinical quality practice
Clinical Research: how we work in this sector
xFDA supports sponsors, CROs and sites on clinical quality: GCP and BIMO expectations, sponsor oversight, vendor and CRO quality, clinical quality systems, audits, CAPA, data integrity and remediation. The emphasis is on building oversight evidence contemporaneously, so it exists when it is needed.
Clinical quality systems & GCP
The quality system behind the study: procedures, roles, escalation and the records that demonstrate control.
- Clinical quality system design and assessment
- GCP procedure development and remediation
- Protocol deviation classification and analysis
- Clinical CAPA and effectiveness verification
- Quality management planning for the study or programme
Sponsor oversight & vendor quality
Delegation transfers the activity, not the responsibility — and the oversight record has to show it.
- CRO and vendor qualification frameworks
- Quality agreements and delegation documentation
- Oversight metrics, review cadence and escalation thresholds
- Monitoring report review and trending
- Vendor performance remediation
Clinical audits & data integrity
Independent examination of sites, vendors and systems against BIMO expectations.
- Sponsor, CRO, vendor and site audits
- Trial master file review and reconstruction
- Clinical data integrity and source traceability
- Safety reporting timeline verification
- Audit finding remediation and follow-through
Typical engagements
Sponsor oversight assessment
Review of delegation documentation, oversight metrics and escalation practice across the vendor set, with the gaps that would be visible in a BIMO review identified.
Clinical quality system build
For sponsors running their first pivotal programme: the procedures, oversight records and CAPA practice needed before the data have to stand on their own.
Clinical Quality & BIMO Readiness Review
Have a clinical quality specialist review your oversight model, vendor management and clinical quality system against BIMO expectations.
Expert Answers
Clinical Research: answered by our consultants
- What is the role of BIMO in clinical quality oversight?FDA's Bioresearch Monitoring program evaluates whether clinical data submitted to the Agency were generated under adequate controls — covering sponsors, monitors, CROs, investigators and IRBs. For a sponsor, BIMO expectations are best treated as the design specification for the clinical quality system, not as an inspection exercise.
- What does adequate CRO and vendor oversight look like?A documented qualification decision, a quality agreement that names deliverables and escalation paths, periodic review of the vendor's performance against defined metrics, and a record of what the sponsor did when performance slipped.
Questions we are asked
Clinical Research: common questions
Direct answers from the consultants who do this work.
- What does BIMO focus on at a sponsor versus a site?
- At a sponsor, the focus is oversight: monitoring, vendor management, safety reporting, protocol adherence and how deviations were handled. At a site, the focus is whether the subjects were protected and whether source records support what was submitted.
- What is the most common clinical data integrity problem?
- Source documentation that does not reconstruct the study conduct — missing contemporaneous notes, corrections without attribution, and electronic systems whose audit trails are never reviewed by anyone accountable.
- How should a sponsor evidence CRO oversight?
- Through documented review of monitoring visit reports, defined escalation paths, quality agreements, periodic vendor performance review with metrics, and evidence that identified issues resulted in action. Contracts alone do not demonstrate oversight.
- Do clinical organizations need a formal CAPA system?
- They need a defined process for analyzing significant deviations for systemic cause and acting on them. It does not have to look like a manufacturing CAPA system, but it does have to show analysis, action and verification of effectiveness.
- Can you audit investigator sites?
- Yes — for-cause and routine site audits, along with practical corrective action support for the site and the sponsor rather than a findings list handed over without a path forward.
Technical guidance for this sector
Newsletter
Insights from Former FDA & Industry Experts
Practical perspectives on GMP, quality systems, validation, manufacturing and development — written by the consultants doing the work. No newsletter-only sales pitches.
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.